



## Article

# Thyroid Hormone Effect on the Differentiation of Human Induced Pluripotent Stem Cells into Hepatocyte-Like Cells

Mariia S. Bogacheva<sup>1</sup>, Margarita A. Bystriakova<sup>1</sup> and Yan-Ru Lou<sup>1,2,\*</sup>

<sup>1</sup> Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, 00014 Helsinki, Finland; mariia.bogacheva@helsinki.fi (M.S.B.); margarita.bystriakova@gmail.com (M.A.B.)

<sup>2</sup> Department of Clinical Pharmacy and Drug Administration, School of Pharmacy, Fudan University, Shanghai 201203, China

\* Correspondence: yanru\_lou@fudan.edu.cn

**Abstract:** Human induced pluripotent stem cells (hiPSCs) hold great potential as an unlimited source for obtaining hepatocyte-like cells (HLCs) for drug research. However, current applications of HLCs have been severely limited by the inability to produce mature hepatocytes from hiPSCs in vitro. Thyroid hormones are one of the hormones that surge during the perinatal period when liver maturation takes place. Here we assessed the influence of thyroid hormone on hepatic progenitor differentiation to HLCs. We analyzed gene and protein expression of early and late hepatic markers and demonstrated the selective activity of thyroid hormone on different genes. Particularly, we demonstrated thyroid hormone-dependent inhibition of the fetal hepatic marker AFP. Our study sheds light on the role of thyroid hormone during liver differentiation and maturation.

**Keywords:** thyroid hormone; hepatic development; human induced pluripotent stem cells; hepatocyte-like cells; liver maturation



**Citation:** Bogacheva, M.S.; Bystriakova, M.A.; Lou, Y.-R. Thyroid Hormone Effect on the Differentiation of Human Induced Pluripotent Stem Cells into Hepatocyte-Like Cells. *Pharmaceuticals* **2021**, *14*, 544. <https://doi.org/10.3390/ph14060544>

Academic Editor: Saima Imran

Received: 4 May 2021

Accepted: 3 June 2021

Published: 7 June 2021

**Publisher's Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Copyright:** © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

## 1. Introduction

Human pluripotent stem cell (hPSC)-derived hepatocyte-like cells (HLCs) represent a promising cell model for drug research [1,2] and various biomedical applications [3,4]. Induction of HLCs in vitro includes the use of soluble factor-based differentiation cocktail and the culture condition which are aiming to mimic the natural liver development in the embryogenesis. It is a multistage process which, first, requires the formation of definitive endoderm (DE), hepatic progenitors, fetal hepatocytes, and finally, HLCs. Every subsequent stage is regulated by the carefully adjusted combinations of growth factors specific for this particular stage of the development [5]. In vivo DE development is initiated by the Nodal signaling [6], which is mimicked in vitro by administration of activin A alone [7], or in combination with the glycoprotein Wnt-3A or bone morphogenetic proteins (BMP) [8,9], or by small molecule sodium butyrate [10], or by the administration of the GSK3 inhibitor CHIR99021 [11].

Furthermore, DE cells undergo hepatic specification using different combinations of BMPs and fibroblast growth factor 4 (FGF4) [5,12–14]. The obtained hepatic progenitors are further differentiated using hepatocyte growth factor (HGF) [12]. Additionally, hepatic maturation requires the presence of interleukin-6 family growth factor OSM and synthetic glucocorticoid dexamethasone (DEX) [15]. BMP7 promotes the key liver protein albumin expression [16]. Undesired formation of cholangiocytes can be prevented by inhibiting the NOTCH and Wnt signaling [17].

Differentiation of hPSCs into HLCs in two-dimensional culture includes switching of the culture matrix after the formation of DE cells (usually Matrigel [18,19]) to the matrix which better mimics the extracellular matrix (ECM) of hepatic progenitors [5,13,20]. The existing protocols for in vitro hepatic differentiation of hPSCs often result in an immature cell population, although this research area is actively developing, and many research

groups have come up with various improvements [12,21,22] and have assessed different components for the differentiation medium [11].

At birth and shortly after birth, most hepatic functions rapidly elevate due to dramatic changes from intrauterine to extrauterine [20]. Fetus–newborn transition involves endocrine, metabolic, cardiovascular, and lung adaptations [21]. Cortisol, catecholamines, and thyroid hormones (THs) are the main modulators in endocrine adaptation [21]. It is well known that THs participate in organ development [22]. The role of THs, including 3,5,3'-triiodothyronine ( $T_3$ ) and 3,5,3',5'-tetraiodothyronine ( $T_4$ ), in tissue development and maturation has been demonstrated in detail in bone, brain, intestine, heart, and pancreas.  $T_3$  was found to induce the maturation of mouse embryonic stem cell (mESC) and human induced PSC (hiPSC)-derived cardiomyocytes [23,24] and promote pancreatic  $\beta$ -cell maturation in rats [25]. It was used to improve the in vitro maturation of hPSC-derived pancreatic  $\beta$ -cells and fetal islet cells [26–28].  $T_3$  has been shown to induce the differentiation of rat liver progenitor oval cells into hepatocytes [29]. THs are known to be actively involved in the process of liver regeneration [30]. They activate and suppress in summary 55 hepatic genes through the interaction with the nuclear TH receptors (TRs)  $TR\alpha$  and  $TR\beta$  [30]. Thus, THs regulate the metabolism of carbohydrates and fatty acids, insulin action, cell proliferation, immune functions, synthesis of glycoproteins, et al. [31]. In mice, it was shown that  $T_3$  stimulates the mitotic activity of the transplanted hepatocytes [32] through the  $TR\beta$  [33].


In early embryo development, the fetus receives THs from the maternal placenta and synthesizes them by itself in the late stages [34,35]. The human placenta is rich in TH transporters, which explains its permeability for THs. THs, in their turn, are actively involved in the processes of tissue differentiation and maturation [36].

The conversion of the inactive  $T_4$  form of TH into an active one  $T_3$  is mediated by the tissue-specific deiodinases DIO1, DIO2, and DIO3. DIO3 is a fetal liver enzyme that plays an important role in the protection of the embryo from the excessive concentrations of maternal THs supplied through the placenta [36]. DIO3 activity decreases from fetal to mature liver, being high in preterm infants and absent in full-term infants [35].

We hypothesized that the TH administration to the hPSCs at certain stages of hepatic differentiation can improve the maturity of resulted HLCs. In this study, we conducted the differentiation of hiPSC into HLCs and demonstrated how  $T_3$  affected the expression of certain markers during the differentiation.

## 2. Results and Discussion


We conducted the hepatic differentiation of hiPSC line GM23720B to study the influence of  $T_3$  hormone on hepatocyte differentiation in vitro (Figure S1A). Before starting the differentiation, we ensured that GM23720B cells displayed the characteristic stem cell colony organization (Figure S1B) and positive protein expression of the stemness markers OCT4 and NANOG (Figure 1). We implemented the differentiation of the hiPSC into HLCs with and without the treatment with  $T_3$  hormone at the defined stages of differentiation.



**Figure 1.** Expression of OCT4 and NANOG proteins in undifferentiated GM23720B cells. Nuclei of cells were stained with DAPI (blue). Proteins of interest were stained either with Alexa Fluor 488 (OCT4), shown in green, or with Alexa Fluor 594 (NANOG), shown in red. Scale bars = 100  $\mu$ m.

### 2.1. DE Induction

The first step of hepatic differentiation is the formation of DE cells. Earlier, we have developed a protocol for the hPSC differentiation into DE cells [19]. It involved treatment with AA during six days. This protocol enables obtaining highly viable cells with high expression of DE cell-specific markers and potency to be differentiated into HLCs, and, therefore, has been implemented in the current study. At day 6 of the differentiation, GM-23720B-derived cells acquired characteristic DE morphology and, based on confluency, possessed high viability, allowing further differentiation procedure (Figure S1B, day 6). At day 6 of the differentiation, GM23720B cells became positive with DE cell markers SOX17, HNF3B, and CXCR4 proteins (Figure 2), indicating the efficient DE cell formation.



**Figure 2.** Expression of SOX17, HNF3B, and CXCR4 proteins in GM23720B-derived cells at day 6 (DE stage) of the differentiation. Nuclei of cells were stained with DAPI (blue). Proteins of interest were stained with Alexa Fluor 594 (red). Scale bars = 100  $\mu$ m.

## 2.2. Hepatic Specification (Generation of Hepatic Progenitors)

The ECM is a dynamic structure and, during embryo development, it remodels itself according to current tissue requirements. Therefore, it is essential to adjust the culture's physical conditions to mimic the natural development process. It is shown that the hepatic progenitor-like environment is beneficial for the differentiation of DE cells to hepatic lineage [5]. Therefore, at the second step of the differentiation, we transferred DE cells from Matrigel to the LN521 matrix, which was shown to be a suitable matrix for the hepatic specification in a previous study, and followed the previously described procedure for the formation of hepatic progenitors [5]. BMP2, BMP4, and FGF proteins act in a concerted manner, regulating the hepatic specification of DE cells [37]. It has been shown to be effective in in vitro experiments for hepatic induction [5,38]. We modified the culture medium with the growth factor combination of BMP2, BMP4, and FGF4 to mimic the hepatogenesis process. By day 10, we observed the change of morphology: the cells became heterogeneous, and cell types were grouped in clusters, some cells started to acquire polygonal shape (Figure S1B, day 10).

### 2.3. Differentiation and Maturation of Hepatic Progenitors

#### 2.3.1. Optimization of the T<sub>3</sub> Concentration

T<sub>3</sub> activates the transcription of genes through the interaction with nuclear TRs that serve as transcription factors in a ligand-dependent manner for the T<sub>3</sub>-responsive genes [39]. T<sub>3</sub> was shown to induce hepatic differentiation in fetal liver [29] and liver regeneration [30]. We thus hypothesized that T<sub>3</sub> administration during the expansion and maturation of hepatic progenitors may positively affect the expression of specific hepatic genes and proteins.

To find the optimal T<sub>3</sub> hormone concentration for the improvement of hepatic maturation, we tested four T<sub>3</sub> concentrations (1 nM, 10 nM, 100 nM, and 1000 nM) and three administration timing intervals (from day 9 to day 22, from day 13 to day 22, and from day 17 to day 22). We performed hepatic differentiation of GM23720B cells and assessed the influence of different T<sub>3</sub> concentrations and time of its administration by the level of mRNA expression of the key early, midlate, and late hepatic markers.

Alpha-1-fetoprotein (AFP), a marker of the early hepatic development, is supposed to decrease by the end of the differentiation experiment, meaning the natural switch from fetal stage to the adult stage of hepatocytes. The lowest *AFP* mRNA expression by the end of the differentiation was obtained using the administration of 1000 nM T<sub>3</sub> from day 9 until day 22 (Figure S2A).

The rise of the expression of midlate marker albumin *ALB* indicates further hepatic differentiation. The highest *ALB* induction in the cells was obtained after the treatment with 1 nM and 100 nM T<sub>3</sub> from day 13 to day 22 (Figure S2B). The highest level of TH responsive *THRSP* (or *SPOT14*), whose expression characterizes adult hepatocytes, was achieved by the treatment with 1000 nM T<sub>3</sub> from day 9 to day 22 (Figure S2C). The expression of *CK19*, the marker of the bile duct epithelium and hepatic progenitors, should decrease after the hepatic progenitor stage. *CK19* expression in all the conditions decreased after day 9, though the level at the end of differentiation was higher than that in primary human hepatocytes (PHH). The lowest expression was achieved by treating cells with 10 nM T<sub>3</sub> from day 13 or 17 to day 22 and with 1000 nM T<sub>3</sub> from day 17 to day 22 (Figure S2D). T<sub>3</sub> treatment did not affect the liver-specific marker *AAT* induction, which decreased after day 17 in both treated and nontreated cells (Figure S2E).

We did not find a universal hormone concentration that upregulates midlate and all the late markers and, at the same time, downregulates the early markers. Although the treatment with the highest T<sub>3</sub> concentration slightly decreased *AAT* expression, it dramatically increased *THRSP* and decreased *AFP*, while *ALB* upregulation depended on the timing of the T<sub>3</sub> treatment. *CK19* downregulation also relied on the later administration of the moderate concentration of T<sub>3</sub>. Thus, we chose to use 1000 nM T<sub>3</sub> from day 9 to day 13 and 10 nM T<sub>3</sub> from day 13 onwards. We observed the hepatic mature and immature gene expression pattern change until day 17 (Figure S3). We found no significant decrease of *AFP* by day 17 (Figure S3A). *ALB* gene expression has increased from day 9 to day 17 without the T<sub>3</sub> treatment, however, no significant difference was found in *ALB* expression dynamics between T<sub>3</sub>-treated and nontreated cells (Figure S3B). No difference was found between T<sub>3</sub>-treated and nontreated cells in *CK19* and *THRSP* expression (Figures S3C and S3E). *CYP3A4* expression increased after day 13 in both treated and nontreated cells (Figure S3D). We suggest that a 17-day differentiation procedure is not enough for the cells to acquire maturity status, and thus subsequently implemented the 22-day differentiation protocol (Figure S1A).


Distinctive hepatocyte morphology is characterized by polarization, polygonal cell shape, and round nucleus [10]. Each cell should be connected with the adjacent cell through tight junction. By day 22 T<sub>3</sub>-treated and nontreated cells increased in size and developed more flat cell areas. Many polygonal cells contained vesicular structures (Figure S1B, day 22).

#### 2.3.2. Gene Expression Profiles of GM23720B-Derived Cells

The maturity of iPSC-derived HLCs is generally assessed via the analysis of the downregulation of immature markers and the upregulation of mature liver markers.



*ALB* mRNA expression significantly increased by day 22 compared to day 10 independently of  $T_3$  administration (Figure 3A) indicating the absence of  $T_3$ -mediated regulation of *ALB* expression. *AFP* encodes transporter protein AFP. It is known to be expressed by hepatic progenitors, such as oval cells, and fetal hepatocytes. Its expression is inhibited after birth [12], giving away its functions to ALB. An earlier study showed that  $T_3$  induced rat liver oval cell differentiation into hepatocytes by inducing the expression of HNF4A and reducing the expression of AFP [29]. In our study, *AFP* gene expression level gradually increased after day 10. First, on day 14, we observed a downregulation of *AFP* in cells treated with the  $T_3$  hormone. By day 22, *AFP* was also downregulated by  $T_3$ , though the difference was not statistically significant (Figure 3B). These results indicate that the  $T_3$  hormone downregulated *AFP* during hepatic progenitor differentiation into hepatocytes.



**Figure 3.** The mRNA expression patterns of the mature hepatic (*ALB*, *AAT*, total *HNF4A*, liver *HNF4A*, and *THRSP*), fetal hepatic (*AFP* and *DIO3*) specific markers during hepatic differentiation of GM23720B cells. Relative gene expression was measured by qPCR and normalized with the *RPLP0* housekeeping gene. Fold inductions were calculated with the reference to the stem cell samples (SC).  $n = 3$  biological repeats. Error bars are SD. One-way ANOVA followed by Sidak's multiple comparisons test was used to compare between any pairs. Statistical significance \* adjusted  $p < 0.05$ , \*\* adjusted  $p < 0.01$ , \*\*\* adjusted  $p < 0.001$ , and \*\*\*\* adjusted  $p < 0.0001$  in comparison with SC are shown above bars. Statistically significant differences \* adjusted  $p < 0.05$ , \*\* adjusted  $p < 0.01$ , \*\*\* adjusted  $p < 0.001$ , and \*\*\*\* adjusted  $p < 0.0001$  between days of the differentiation or between the  $T_3$ -containing (+T3) or no  $T_3$  are shown above lines.

At the DE stage, we observed the dramatic upregulation of *DIO3* with the subsequent decrease in upcoming timepoints. After day 10, the expression of *DIO3* decreased in both treated and nontreated cells, and at day 22, there was no difference between the conditions indicating no influence of the  $T_3$  hormone on *DIO3* expression (Figure 3C).

An increase in *AAT* expression in nontreated cells was detected already at day 14 compared to day 10, while in the  $T_3$ -treated cells, it increased only by day 22. However, there was no difference in *AAT* expression by the end of the differentiation between the treated and nontreated cells (Figure 3D).

We did not observe any significant change in the total *HNF4A* expression level during the differentiation (Figure 3E). We assessed the *HNF4A* liver isoform mRNA and found its upregulation in all the conditions after the DE stage of the differentiation. It sharply increased at day 10 with a decrease at day 14 in all the conditions. Furthermore, we did not observe any change or difference in its expression by  $T_3$  treatment (Figure 3F).

TH responsive *THRSP* (or *SPOT14*) was significantly upregulated at day 14 in both conditions and day 22 in  $T_3$ -treated cells. In contrast, nontreated cells did not show an increased level of *THRSP* (Figure 3G). An expected increase in the mature marker *THRSP* expression by  $T_3$  treatment indicates the sensitivity of the cells to the TH and an enhancement of the lipid metabolism function of HLCs [40].

### 2.3.3. Protein Expression in GM23720B-Derived Cells


The protein expression pattern of the GM23720B-derived hepatic cells was studied using two methods: immunohistochemical staining with further visualization using confocal microscopy and Western blotting. Staining of GM23720B-derived hepatic progenitors did not show the difference between  $T_3$ -treated and nontreated cells, both of which had bright staining signals for HNF4A, F-actin, CK18, CK19, AFP, and ALB (Figure 4). It is worth noting that F-actin staining showed polarized polygonal cell morphology after  $T_3$  treatment.

Staining of GM23720B-derived fetal hepatocytes showed that  $T_3$  treatment did not affect the expression of HNF4A, CK18, CK19, and CYP3A4 protein expression.  $T_3$ -treated cells exhibited a polarized polygonal morphology, as seen by F-actin staining and seemed to have weaker CK19, AFP, and ALB signals than the nontreated cells (Figure 5). However, treatment with  $T_3$  hormone dramatically increased the positive NTCP (a sodium/bile acid cotransporter encoded by solute carrier family 10 member 1) signal (Figure 5).

Western blotting analysis demonstrated that without the  $T_3$  treatment, AFP protein expression rose on day 14 and further increased by day 22 (Figure 6A). Cells treated with  $T_3$  possessed significantly lower level of AFP on day 22 than nontreated cells (Figure 6A). ALB levels in both treated and nontreated cells increased from day 14 to day 22. On day 22 there was no difference in ALB intensity between  $T_3$ -treated and nontreated cells (Figure 6B). The relative intensity of HNF4A (all isoforms) rose at day 10 and then decreased by day 14 in the case of nontreated cells.  $T_3$ -treated cells decreased the HNF4A intensity from day 14 to day 22 (Figure 6C). CK19 was upregulated at day 10 and then decreased by day 22 in nontreated cells.  $T_3$  treatment did not change CK19 protein expression (Figure 6D).


The postnatal repression of fetal-specific liver genes is one of the key mechanisms for liver maturation [41]. A recent study dedicated to the enhancement of hiPSC-derived HLCs maturity and functionality showed the improvement of metabolic functions, but the expression of *AFP* increased at the stage of hepatic progenitors and remained high until the end of the differentiation [42]. Previously,  $T_3$  was found to decrease *AFP* production and increase *ALB* production in mouse fetal liver cells [43]. In our protocol, the fold induction of *ALB* expression in hiPSC-derived HLCs was higher than in a previously published study using growth factor cocktail for the hepatic differentiation of hPSC [44]. Although, in our study,  $T_3$  did not significantly decrease the mRNA expression of *AFP* by the end of the differentiation, the treatment with  $T_3$  resulted in a decrease of *AFP* protein level in HLCs. We speculate that it might be affected by the increase of post-transcriptional *AFP* repression indirectly caused by  $T_3$  action. However, the suppressive effect of  $T_3$  on

AFP expression is visible at the stage of fetal hepatocytes when cells were subjected to a higher concentration of  $T_3$ . The hepatocyte-specific NTCP is an essential membrane transporter for bile acids [45]. In the current study, the upregulation of NTCP may indicate the promotion of hepatic maturation by  $T_3$ . The induction of NTCP is highly important for the liver cell model for drug research due to its role in various liver diseases [45] and hepatitis B and D viruses entry [46]. However,  $T_3$  did not regulate the major serum protein ALB.




**Figure 4.** Expression of HNF4A, F-actin, CK18, CK19, AFP, and ALB proteins in GM23720B-derived cells at day 13 (hepatic progenitor stage) of the differentiation with or without  $T_3$  hormone in differentiation medium. Nuclei of cells were stained with DAPI (blue). Proteins of interest were stained either with Alexa Fluor 488 (HNF4A, CK18, and AFP), shown in green, or with Alexa Fluor 594 (F-actin, CK19, and ALB), shown in red. Scale bars = 100  $\mu$ m.





**Figure 5.** Expression of HNF4A, F-actin, CYP3A4, CK18, CK19, NTCP, AFP, and ALB proteins in GM23720B-derived cells at day 17 (fetal hepatocyte stage) of the differentiation with or without T<sub>3</sub> hormone in differentiation medium. Nuclei of cells were stained with DAPI (blue). Proteins of interest were stained either with Alexa Fluor 488 (HNF4A, CYP3A4, CK18, and AFP), shown in green, or with Alexa Fluor 594 (F-actin, CK19, NTCP, and ALB), shown in red. Scale bars = 100  $\mu$ m.



**Figure 6.** Western blotting analysis of AFP, ALB, HNF4A, and CK19 proteins in GM23720B cells and their derivatives during the hepatic differentiation at five timepoints. (A–D) The relative protein intensity normalized against GAPDH. The relative intensity at day 14 was set to 1.  $n = 3$  biological repeats. Error bars are SD. One-way ANOVA followed by Sidak's multiple comparisons test was used to compare between any pairs. Statistical significance \* adjusted  $p < 0.05$ , \*\* adjusted  $p < 0.01$ , \*\*\* adjusted  $p < 0.001$ , and \*\*\*\* adjusted  $p < 0.0001$  in comparison with SC are shown above bars. (E) Representative membrane picture of three independent experiments.

### 3. Materials and Methods

#### 3.1. Cell Line

We purchased hiPSC line GM23720B from Coriell Institute (USA). Cell culture was performed on Matrigel matrix (BD Biosciences) with daily mTeSR<sup>TM</sup>1 (STEMCELL<sup>TM</sup> Technologies) medium change. Subculture was done every three–four days using Versene solution 1:5000 (Invitrogen, 15040033) for cell detachment.

#### 3.2. Hepatic Differentiation

Stem cells were differentiated to DE in RPMI-1640 medium (Gibco, 31870–025, Carlsbad, CA) supplemented with  $1 \times$  GlutaMAX<sup>TM</sup> (Gibco, 35050–038), 100 ng/mL activin A (AA) (PeproTech, 120-14E), and  $1 \times$  B-27 (Gibco, 17504–044) as described previously [19]. At day 5 or 6 DE cells were detached using enzyme-free cell dissociation buffer (Gibco, 13151-014) for 15 min at 37 °C and transferred on the laminin-521 (LN521, Biolamina) coating by following a previously published protocol [5]. LN521 dilution was prepared in  $1 \times$  DPBS with  $\text{Ca}^{+}$  and  $\text{Mg}^{+}$  (final concentration is 10  $\mu\text{g}/\text{mL}$ ) and incubated in culturing wells either overnight at +4 °C (slow coating) or for two hours at +37 °C (fast coating). DE cells were detached with the enzyme-free Cell Dissociation Buffer (Gibco, 13151-014) for 15 min at +37 °C. Then they were seeded on LN521 at the density  $7.47 \times 10^4$  cells/cm<sup>2</sup> and cultured in Hepatocyte Culture Medium (HCM<sup>TM</sup> SingleQuots<sup>TM</sup> Kit; Lonza CC-4182, without rhEGF and gentamicin-amphotericin-1000) supplemented with 5 ng/mL fibroblast growth factor 4 (FGF4, PeproTech, 100-31), 10 ng/mL bone morphogenetic protein 2 (BMP2, Pepro-Tech, 120-02), and 10 ng/mL BMP4 (PeproTech, 120-05) for four days with daily

medium change to obtain hepatic progenitors. Then hepatic progenitors were cultured in HCM supplemented with 10 ng/mL hepatocyte growth factor (HGF, PeproTech, 100-39), 10 ng/mL Oncostatin M (OSM, PeproTech, 300-10T), and 0.1 mM Dexamethasone (DEX, Sigma-Aldrich, D4902) for four days to get immature hepatocytes. Culture medium was renewed every second day. These cells were cultured in HCM supplemented with 10 ng/mL OSM, 25 ng/mL bone morphogenetic protein 7 (BMP7, PeproTech, 120-03), 0.1 mM DEX, and 10  $\mu$ M DAPT (Tocris, 2634) in DMSO for four days. Culture medium was changed every second day. Finally, the cells were cultured in HCM medium supplemented with 25 ng/mL BMP7, 0.1 mM DEX, and 10  $\mu$ M DAPT in DMSO for five days. We changed the culture medium every second day. To find the optimal T<sub>3</sub> hormone concentration for the improvement of hepatic maturation, we first tested four concentrations of triiodothyronine (T<sub>3</sub>; Sigma, T6397-100MG) hormone in HBSS buffer (Gibco, 14025-050) (1 nM, 10 nM, 100 nM and 1000 nM) and three administration timing intervals (from day 9 to day 22, from day 13 to day 22, and from day 17 to day 22). After qPCR assessment of hepatic markers, we chose to use 1000 nM T<sub>3</sub> from hepatic progenitor stage for four days followed by 10 nM T<sub>3</sub> for the rest of differentiation period (Figure S1A). During T<sub>3</sub> treatment, 1000 nM or 10 nM T<sub>3</sub> in HBSS was added into cell culture wells daily.

### 3.3. RNA Isolation and cDNA Conversion

We isolated RNA from cells at five timepoints of the differentiation: stem cells (day 0), DE stage (day 6), hepatoblasts stage (day 10), fetal hepatocytes (day 14), and adult hepatocyte-like cell stage (day 22). Cells were lysed using TRI-reagent (Zymo-research, R2050-1-50). Thereafter, RNA was isolated using a Direct-zol RNA MicroPrep kit (Zymo-research, R2060) accordingly to the manufacturer's instruction. Human fetal liver (HFH) mRNA was purchased from BioChain (lot numbers are HFH1: A601605, HFH2: A601607, and HFH3: B210099) and primary human hepatocyte (PHH) mRNA samples were isolated from PHHs (BD Gentest™, PHH1: #454503, lot 95; PHH2: #454503, lot 99; PHH3: #454426, lot 453251202). RNA concentration was measured with NanoDrop™ One (Thermo Scientific). The cDNA conversion was made with a High-Capacity cDNA reverse transcription kit (Applied Biosystems, 4368814).

### 3.4. Quantitative PCR (qPCR)

A StepOnePlus Real-Time PCR System (Applied Biosystems) machine was used for performing qPCR reactions of the cDNA samples using either a PowerUp SYBR Green Master Mix (Applied Biosystems, A25741) or TaqMan Gene Expression Master Mix (Applied Biosystems, 4369016). After qPCR using PowerUp SYBR Green Master Mix the target specificity was assessed by melting curves. For the relative gene expression calculation, a housekeeping gene ribosomal protein, large, P0 (*RPLP0*) was used. All the used primers and TaqMan® Gene Expression Assay mixes are listed in Tables S1 and S2, respectively. All primers were designed by Primer Express v2.0 software (Applied Biosystems) [5], and they were synthesized by Oligomer Oy (Helsinki, Finland) or Metabion (Planegg, Germany). The relative quantification of each target gene in comparison with the housekeeping gene was made by a standard curve method based on a published mathematical model [47]. The standard curve method calculates the actual amplification efficiency, which is then taken into the calculation of relative gene expression. The mean expression values in undifferentiated stem cells (Day 0) were set as one and used as a reference for the calculation of the relative gene expressions in followed timepoints.

### 3.5. Protein Isolation

Protein samples were collected from cells at five time points: stem cells (day 0), DE stage (day 6), hepatoblast stage (day 10), fetal hepatocyte stage (day 14), and adult HLC stage (day 22). Cells were lysed using a 1x protease inhibitor cocktail (Sigma Aldrich, P8340) in Pierce RIPA buffer (Thermo Scientific, 89901) for 10 min on ice. Thereafter, samples were centrifuged at 14000 g for 15 min at +4 °C to pellet the cell debris. The

supernatant was collected and frozen. Protein concentration was calculated based on absorbance measurement using a Pierce BCA Protein Assay Kit (Thermo Scientific, 23227) according to the instruction. The absorbance was detected on a Varioscan LUX device with Scanit 6.0 program.

### 3.6. Western Blot Analysis

Protein samples were diluted in  $4 \times$  Laemmli buffer (Bio-rad, 1610747) with 10%  $\beta$ -mercaptoethanol. Protein samples (5  $\mu$ g) and PageRuler Plus Prestained Protein Ladder (Thermo Fisher Scientific, 26619, 5  $\mu$ L) were loaded into the Mini-PROTEAN TGX Stain-free precast gel 4–20% (Bio-rad, 4568096) and run at voltage 125 V for approximately 90 min in a Mini-PROTEAN device. Thereafter, the gel was electroblotted to a 0.2  $\mu$ m nitrocellulose membrane using a Trans-Blot Turbo Mini Nitrocellulose Transfer Pack (Bio-rad, 1704158) on a Trans-Blot Turbo Blotting System using a built-in program. Blocking was accomplished in a 5% milk solution. The membranes were incubated with the primary antibody dilution in 1% milk overnight at +4 °C and, thereafter, with the secondary antibody dilution in 1% milk for 1 h at +25 °C. After each antibody incubation stage, membranes were washed with TBS-T three times for 15 min. The antibodies used in Western blotting in the current study are listed in Table S3. A Clarity Western ECL Substrate kit (Bio-Rad, 1705061) was used for visualization of the secondary antibody signals. Images were taken on a ChemiDoc MP imager (Bio-Rad). Relative quantities of proteins were calculated using Image Lab 6.0.1 (Bio-Rad).

### 3.7. Immunofluorescent Staining

For the immunostaining, cells were cultured and differentiated either in 8-well Lab-Tek<sup>®</sup> Chamber Slide<sup>™</sup> systems (Nunc, 177445, Roskilde, Denmark) or in black 96-well  $\mu$ -plates (ibid, 89626, Planegg/Martinsried, Germany). The cells were fixed at the stage of undifferentiated SCs (day 0), DE (day 5), hepatic progenitor stage (day 13), and fetal hepatocyte stage (day 17). Fixation with 4% paraformaldehyde for 10 min was followed by permeabilization either with 0.1% Triton X-100 or with 0.5% Saponin for 10 min. The blocking step was made by 10% normal goat or donkey serum (Millipore, Burlington, MA) for 1 h. Primary antibody staining was conducted for 24 h at +4 °C, and negative controls included staining with non-immunized normal rabbit IgG (Peprotech 500-P00), goat IgG (Santa Cruz Biotechnology, sc-2018), and mouse IgG (Peprotech 500-M00). Thereafter, cells were stained with the secondary antibodies conjugated with Alexa Fluor 594 or Alexa Fluor 488 (Invitrogen, 1:400) for 1 h at room temperature. Cell nuclei were stained with DAPI (Sigma-Aldrich, D8417, 12.5  $\mu$ g/mL in MilliQ water) for 2 min. Cells in chamber slides were mounted with a Vectashield mounting medium (Vector, H-1500). Samples in 96-well  $\mu$ -plates were filled up with 1xDPBS. The protein expression was visualized using a confocal microscope Leica TCS SP5II HCS A with aHCX PL APO 20 $\times$ /0.7 objective. DAPI was excited with UV (diode 405 nm/50 mW), Alexa Fluor 488 with an Argon 488 nm laser, and Alexa Fluor 594 with a DPSS (561 nm/20 mW) laser. Primary and secondary antibodies are listed in Table S4.

### 3.8. Statistical Analysis

Statistical analyses were performed using GraphPad Prism 8 software. Statistical significance was determined by one-way analysis of variance (ANOVA) followed by Sidak's multiple comparisons test. Differences of adjusted  $p < 0.05$  (\*), adjusted  $p < 0.01$  (\*\*), adjusted  $p < 0.001$  (\*\*\*), and adjusted  $p < 0.0001$  (\*\*\*\*) were considered significant.

## 4. Conclusions

Taken together, T<sub>3</sub> at the chosen concentrations selectively influenced the expression of fetal marker AFP and maturation markers THRSP and NTCP during the differentiation of hiPSCs into HLCs in vitro. To make a thorough examination of the T<sub>3</sub> action during hepatic differentiation and maturation of hiPSCs, more liver markers and functions need

to be measured, such as drug metabolizing enzymes, glycogen production, and albumin secretion. Based on the current results, we cannot make a concrete conclusion that the treatment of T<sub>3</sub> can improve hepatic maturation. The physiological changes during the perinatal period involve not only the surge of THs, but also changes in other hormones and growth factors. The use of T<sub>3</sub> during in vitro hPSC differentiation may not be sufficient to generate mature hepatocytes. Complete hepatic maturation requires a cocktail of optimal hormones and growth factors. In addition, the T<sub>3</sub> effect on the expression of genes and proteins need to be further studied. The use of TR antagonists and gene knockout cells can elucidate the role of TRs and downstream molecules. Our recent study offers a method to efficiently generate knockout hPSC lines by CRISPR/Cas 9 genome editing technology [48]. Previously, liver gene regulation by TH has been studied in human fatty liver [49] and rodents [50,51]. To the best of our knowledge, this is the first study addressing T<sub>3</sub> influence on hepatic differentiation of hiPSCs in vitro.

**Supplementary Materials:** The followings are available online at <https://www.mdpi.com/article/10.3390/ph14060544/s1>, Figure S1. Hepatic differentiation of the hiPSC line GM23720B. A: Scheme of the optimized differentiation protocol. Beginning from day 10 cells were differentiated either without T<sub>3</sub> hormone (a) or with T<sub>3</sub> hormone (b) in the medium. B: The morphological changes of GM23720B and their derivatives during hepatic differentiation. Pictures were taken at five timepoints (day 0, day 6, day 10, day 14, and day 22). Scale bars = 100 µm. Figure S2. The preliminary assessment of the T<sub>3</sub> action at different concentrations and at different timepoints. The mRNA expression patterns of the mature hepatic (*ALB*, *THRSP*, and *AAT*), fetal hepatic (*AFP*), and hepatic progenitor (*CK19*) specific markers during hepatic differentiation of GM23720B cells. Relative gene expression was measured by qPCR and normalized with the *RPLP0* housekeeping gene. Fold inductions were calculated with the reference to the undifferentiated stem cell samples (Day 0). N = 1 biological repeat. HFH: human fetal hepatocyte; PHH: primary human hepatocyte. Figure S3. The comparison of two time intervals (from day 9 to day 13 and from day 13 to day 17) of the T<sub>3</sub> administration. The T<sub>3</sub> action was assessed by the mRNA expression patterns of the mature hepatic (*ALB*, *CYP3A4*, and *THRSP*), fetal hepatic (*AFP*), and hepatic progenitor (*CK19*) specific markers during 17 days of the hepatic differentiation of GM23720B cells. Relative gene expression was measured by qPCR and normalized with the *RPLP0* housekeeping gene. Fold inductions were calculated with the reference to the undifferentiated stem cell samples (Day 0). N = 3 biological repeats. Error bars are SD. One-way ANOVA followed by Sidak's multiple comparisons test was used to compare between any pairs. Statistical significance \* adjusted  $P < 0.05$  and \*\*\*\* adjusted  $P < 0.0001$  in comparison with Day 0 are shown above bars. Statistically significant differences \* adjusted  $P < 0.05$  and \*\*\*\* adjusted  $P < 0.0001$  between days of the differentiation are shown above lines.

**Author Contributions:** Y.-R.L. conceived, designed, and supervised the research, carried out some of the experiments. M.S.B. carried out most of the experiments and analyzed the data and wrote the first draft of the manuscript. Y.-R.L. edited the manuscript. M.A.B. helped in some cell culture experiments, performed Western blotting, and protein quantification. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research was funded by Finnish National Agency for Education, grant number TM-18-10922.

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** Not applicable.

**Acknowledgments:** This work was supported by the grants from Finnish National Agency for Education (decision 10.10.2018/TM-18-10922 to Y.-R.L. for M.A.B.), Fudan University, and University of Helsinki. M.S.B. and Y.-R.L. acknowledge the Doctoral Programme in Drug Research for providing M.S.B. a Ph.D. student position at the Faculty of Pharmacy, University of Helsinki. We would like to thank the Light Microscopy Unit at the Institute of Biotechnology for providing confocal microscopy and Päivi Tammela for providing NanoDrop™ One and ChemiDoc MP imager.

**Conflicts of Interest:** The authors declare no competing interest.



## References

1. Williams, D.P. Application of hepatocyte-like cells to enhance hepatic safety risk assessment in drug discovery. *Philos Trans. R Soc. Lond. B Biol. Sci.* **2018**, *373*. [[CrossRef](#)]
2. Donato, M.T.; Tolosa, L. Stem-cell derived hepatocyte-like cells for the assessment of drug-induced liver injury. *Differ. Res. Biol. Divers.* **2019**, *106*, 15–22. [[CrossRef](#)]
3. Fu, G.B.; Huang, W.J.; Zeng, M.; Zhou, X.; Wu, H.P.; Liu, C.C.; Wu, H.; Weng, J.; Zhang, H.D.; Cai, Y.C.; et al. Expansion and differentiation of human hepatocyte-derived liver progenitor-like cells and their use for the study of hepatotropic pathogens. *Cell Res.* **2019**, *29*, 8–22. [[CrossRef](#)]
4. Deguchi, S.; Takayama, K.; Mizuguchi, H. Generation of Human Induced Pluripotent Stem Cell-Derived Hepatocyte-Like Cells for Cellular Medicine. *Biol. Pharm. Bull.* **2020**, *43*, 608–615. [[CrossRef](#)] [[PubMed](#)]
5. Kanninen, L.K.; Harjumaki, R.; Peltoniemi, P.; Bogacheva, M.S.; Salmi, T.; Porola, P.; Niklander, J.; Smutny, T.; Urtti, A.; Yliperttula, M.L.; et al. Laminin-511 and laminin-521-based matrices for efficient hepatic specification of human pluripotent stem cells. *Biomaterials* **2016**, *103*, 86–100. [[CrossRef](#)]
6. Shen, M.M. Nodal signaling: Developmental roles and regulation. *Development* **2007**, *134*, 1023–1034. [[CrossRef](#)]
7. D'Amour, K.A.; Agulnick, A.D.; Eliazar, S.; Kelly, O.G.; Kroon, E.; Baetge, E.E. Efficient differentiation of human embryonic stem cells to definitive endoderm. *Nat. Biotechnol.* **2005**, *23*, 1534–1541. [[CrossRef](#)]
8. Hay, D.C.; Fletcher, J.; Payne, C.; Terrace, J.D.; Gallagher, R.C.; Snoeys, J.; Black, J.R.; Wojtacha, D.; Samuel, K.; Hannoun, Z.; et al. Highly efficient differentiation of hESCs to functional hepatic endoderm requires ActivinA and Wnt3a signaling. *Proc. Natl. Acad. Sci. USA* **2008**, *105*, 12301–12306. [[CrossRef](#)] [[PubMed](#)]
9. Teo, A.K.; Valdez, I.A.; Dirice, E.; Kulkarni, R.N. Comparable generation of activin-induced definitive endoderm via additive Wnt or BMP signaling in absence of serum. *Stem Cell Rep.* **2014**, *3*, 5–14. [[CrossRef](#)] [[PubMed](#)]
10. Hay, D.C.; Zhao, D.; Fletcher, J.; Hewitt, Z.A.; McLean, D.; Urruticoechea-Uriguen, A.; Black, J.R.; Elcombe, C.; Ross, J.A.; Wolf, R.; et al. Efficient differentiation of hepatocytes from human embryonic stem cells exhibiting markers recapitulating liver development in vivo. *Stem Cells* **2008**, *26*, 894–902. [[CrossRef](#)] [[PubMed](#)]
11. Varghese, D.S.; Alawathugoda, T.T.; Ansari, S.A. Fine Tuning of Hepatocyte Differentiation from Human Embryonic Stem Cells: Growth Factor vs. Small Molecule-Based Approaches. *Stem Cells Int.* **2019**, *2019*, 5968236. [[CrossRef](#)]
12. Si-Tayeb, K.; Noto, F.K.; Nagaoka, M.; Li, J.; Battle, M.A.; Duris, C.; North, P.E.; Dalton, S.; Duncan, S.A. Highly efficient generation of human hepatocyte-like cells from induced pluripotent stem cells. *Hepatology* **2010**, *51*, 297–305. [[CrossRef](#)]
13. Kanninen, L.K.; Porola, P.; Niklander, J.; Malinen, M.M.; Corlu, A.; Guguen-Guillouzo, C.; Urtti, A.; Yliperttula, M.L.; Lou, Y.R. Hepatic differentiation of human pluripotent stem cells on human liver progenitor HepaRG-derived acellular matrix. *Exp. Cell Res.* **2016**, *341*, 207–217. [[CrossRef](#)]
14. Huang, J.; Guo, X.; Li, W.; Zhang, H. Activation of Wnt/beta-catenin signalling via GSK3 inhibitors direct differentiation of human adipose stem cells into functional hepatocytes. *Sci. Rep.* **2017**, *7*, 40716. [[CrossRef](#)]
15. Kamiya, A.; Kinoshita, T.; Miyajima, A. Oncostatin M and hepatocyte growth factor induce hepatic maturation via distinct signaling pathways. *FEBS Lett.* **2001**, *492*, 90–94. [[CrossRef](#)]
16. Rossi, J.M.; Dunn, N.R.; Hogan, B.L.; Zaret, K.S. Distinct mesodermal signals, including BMPs from the septum transversum mesenchyme, are required in combination for hepatogenesis from the endoderm. *Genes Dev.* **2001**, *15*, 1998–2009. [[CrossRef](#)]
17. Ang, L.T.; Tan, A.K.Y.; Autio, M.I.; Goh, S.H.; Choo, S.H.; Lee, K.L.; Tan, J.; Pan, B.; Lee, J.J.H.; Lum, J.J.; et al. A Roadmap for Human Liver Differentiation from Pluripotent Stem Cells. *Cell Rep.* **2018**, *22*, 2190–2205. [[CrossRef](#)]
18. Toivonen, S.; Lundin, K.; Balboa, D.; Ustinov, J.; Tamminen, K.; Paldi, J.; Trokovic, R.; Tuuri, T.; Otonkoski, T. Activin A and Wnt-dependent specification of human definitive endoderm cells. *Exp. Cell Res.* **2013**, *319*, 2535–2544. [[CrossRef](#)] [[PubMed](#)]
19. Bogacheva, M.S.; Khan, S.; Kanninen, L.K.; Yliperttula, M.; Leung, A.W.; Lou, Y.R. Differences in definitive endoderm induction approaches using growth factors and small molecules. *J. Cell. Physiol.* **2018**, *233*, 3578–3589. [[CrossRef](#)] [[PubMed](#)]
20. Grijalva, J.; Vakili, K. Neonatal liver physiology. *Semin. Pediatr. Surg.* **2013**, *22*, 185–189. [[CrossRef](#)]
21. Hillman, N.H.; Kallapur, S.G.; Jobe, A.H. Physiology of transition from intrauterine to extrauterine life. *Clin. Perinatol.* **2012**, *39*, 769–783. [[CrossRef](#)] [[PubMed](#)]
22. Mourouzis, I.; Lavecchia, A.M.; Xinaris, C. Thyroid Hormone Signalling: From the Dawn of Life to the Bedside. *J. Mol. Evol.* **2020**, *88*, 88–103. [[CrossRef](#)] [[PubMed](#)]
23. Lee, Y.K.; Ng, K.M.; Chan, Y.C.; Lai, W.H.; Au, K.W.; Ho, C.Y.; Wong, L.Y.; Lau, C.P.; Tse, H.F.; Siu, C.W. Triiodothyronine promotes cardiac differentiation and maturation of embryonic stem cells via the classical genomic pathway. *Mol. Endocrinol.* **2010**, *24*, 1728–1736. [[CrossRef](#)]
24. Yang, X.; Rodriguez, M.; Pabon, L.; Fischer, K.A.; Reinecke, H.; Regnier, M.; Sniadecki, N.J.; Ruohola-Baker, H.; Murry, C.E. Tri-iodo-l-thyronine promotes the maturation of human cardiomyocytes-derived from induced pluripotent stem cells. *J. Mol. Cell Cardiol.* **2014**, *72*, 296–304. [[CrossRef](#)] [[PubMed](#)]
25. Aguayo-Mazzucato, C.; Zavacki, A.M.; Marinelarena, A.; Hollister-Lock, J.; El Khattabi, I.; Marsili, A.; Weir, G.C.; Sharma, A.; Larsen, P.R.; Bonner-Weir, S. Thyroid hormone promotes postnatal rat pancreatic beta-cell development and glucose-responsive insulin secretion through MAFA. *Diabetes* **2013**, *62*, 1569–1580. [[CrossRef](#)] [[PubMed](#)]

26. Aguayo-Mazzucato, C.; DiLenno, A.; Hollister-Lock, J.; Cahill, C.; Sharma, A.; Weir, G.; Colton, C.; Bonner-Weir, S. MAFA and T3 Drive Maturation of Both Fetal Human Islets and Insulin-Producing Cells Differentiated From hESC. *J. Clin. Endocrinol. Metab.* **2015**, *100*, 3651–3659. [[CrossRef](#)]
27. Rezania, A.; Bruin, J.E.; Arora, P.; Rubin, A.; Batushansky, I.; Asadi, A.; O'Dwyer, S.; Quiskamp, N.; Mojibian, M.; Albrecht, T.; et al. Reversal of diabetes with insulin-producing cells derived in vitro from human pluripotent stem cells. *Nat. Biotechnol.* **2014**, *32*, 1121–1133. [[CrossRef](#)]
28. Pagliuca, F.W.; Millman, J.R.; Gurtler, M.; Segel, M.; Van Dervort, A.; Ryu, J.H.; Peterson, Q.P.; Greiner, D.; Melton, D.A. Generation of functional human pancreatic beta cells in vitro. *Cell* **2014**, *159*, 428–439. [[CrossRef](#)]
29. Laszlo, V.; Dezso, K.; Baghy, K.; Papp, V.; Kovalszky, I.; Safrany, G.; Thorgeirsson, S.S.; Nagy, P.; Paku, S. Triiodothyronine accelerates differentiation of rat liver progenitor cells into hepatocytes. *Histochem. Cell Biol.* **2008**, *130*, 1005–1014. [[CrossRef](#)]
30. Gionfra, F.; De Vito, P.; Pallottini, V.; Lin, H.Y.; Davis, P.J.; Pedersen, J.Z.; Incerpi, S. The Role of Thyroid Hormones in Hepatocyte Proliferation and Liver Cancer. *Front. Endocrinol.* **2019**, *10*, 532. [[CrossRef](#)]
31. Feng, X.; Jiang, Y.; Meltzer, P.; Yen, P.M. Thyroid hormone regulation of hepatic genes in vivo detected by complementary DNA microarray. *Mol. Endocrinol.* **2000**, *14*, 947–955. [[CrossRef](#)]
32. Oren, R.; Dabeva, M.D.; Karnezis, A.N.; Petkov, P.M.; Rosencrantz, R.; Sandhu, J.P.; Moss, S.F.; Wang, S.; Hurston, E.; Laconi, E.; et al. Role of thyroid hormone in stimulating liver repopulation in the rat by transplanted hepatocytes. *Hepatology* **1999**, *30*, 903–913. [[CrossRef](#)]
33. Kowalik, M.A.; Perra, A.; Pibiri, M.; Cocco, M.T.; Samarut, J.; Plateroti, M.; Ledda-Columbano, G.M.; Columbano, A. TRbeta is the critical thyroid hormone receptor isoform in T3-induced proliferation of hepatocytes and pancreatic acinar cells. *J. Hepatol.* **2010**, *53*, 686–692. [[CrossRef](#)]
34. Contempre, B.; Jauniaux, E.; Calvo, R.; Jurkovic, D.; Campbell, S.; de Escobar, G.M. Detection of thyroid hormones in human embryonic cavities during the first trimester of pregnancy. *J. Clin. Endocrinol. Metab.* **1993**, *77*, 1719–1722. [[CrossRef](#)] [[PubMed](#)]
35. Richard, K.; Hume, R.; Kaptein, E.; Sanders, J.P.; van Toor, H.; De Herder, W.W.; den Hollander, J.C.; Krenning, E.P.; Visser, T.J. Ontogeny of iodothyronine deiodinases in human liver. *J. Clin. Endocrinol. Metab.* **1998**, *83*, 2868–2874. [[CrossRef](#)]
36. Forhead, A.J.; Fowden, A.L. Thyroid hormones in fetal growth and prepartum maturation. *J. Endocrinol.* **2014**, *221*, R87–R103. [[CrossRef](#)]
37. Kinoshita, T.; Miyajima, A. Cytokine regulation of liver development. *Biochim. Et Biophys. Acta* **2002**, *1592*, 303–312. [[CrossRef](#)]
38. Brolen, G.; Sivertsson, L.; Bjorquist, P.; Eriksson, G.; Ek, M.; Semb, H.; Johansson, I.; Andersson, T.B.; Ingelman-Sundberg, M.; Heins, N. Hepatocyte-like cells derived from human embryonic stem cells specifically via definitive endoderm and a progenitor stage. *J. Biotechnol.* **2010**, *145*, 284–294. [[CrossRef](#)]
39. Davis, P.J.; Goglia, F.; Leonard, J.L. Nongenomic actions of thyroid hormone. *Nat. Rev. Endocrinol.* **2016**, *12*, 111–121. [[CrossRef](#)]
40. Kuemmerle, N.B.; Kinlaw, W.B. THRSP (thyroid hormone responsive). *Atlas Genet. Cytogenet. Oncol. Haematol* **2011**, *15*, 480–482. [[CrossRef](#)]
41. Suzuki, T.; Adachi, S.; Kikuguchi, C.; Shibata, S.; Nishijima, S.; Kawamoto, Y.; Iizuka, Y.; Koseki, H.; Okano, H.; Natsume, T.; et al. Regulation of Fetal Genes by Transitions among RNA-Binding Proteins during Liver Development. *Int. J. Mol. Sci.* **2020**, *21*, 9319. [[CrossRef](#)]
42. Dao Thi, V.L.; Wu, X.; Belote, R.L.; Andreo, U.; Takacs, C.N.; Fernandez, J.P.; Vale-Silva, L.A.; Prallet, S.; Decker, C.C.; Fu, R.M.; et al. Stem cell-derived polarized hepatocytes. *Nat. Commun.* **2020**, *11*, 1677. [[CrossRef](#)] [[PubMed](#)]
43. Anteby, E.; Shpan, P.; Dushnik, M.; Zvang, A.; Zer, T.; Ben-Neriah, Z.; Yagel, S. The regulatory role of tri-iodothyronine on the production of alpha-fetoprotein and albumin by mouse fetal liver cells. *Human Reprod.* **1993**, *8*, 1576–1578. [[CrossRef](#)]
44. Du, C.; Feng, Y.; Qiu, D.; Xu, Y.; Pang, M.; Cai, N.; Xiang, A.P.; Zhang, Q. Highly efficient and expedited hepatic differentiation from human pluripotent stem cells by pure small-molecule cocktails. *Stem Cell Res. Ther.* **2018**, *9*, 58. [[CrossRef](#)]
45. Stieger, B. The role of the sodium-taurocholate cotransporting polypeptide (NTCP) and of the bile salt export pump (BSEP) in physiology and pathophysiology of bile formation. *Handb Exp. Pharmacol.* **2011**, 205–259. [[CrossRef](#)]
46. Li, W. The hepatitis B virus receptor. *Annu. Rev. Cell Dev. Biol.* **2015**, *31*, 125–147. [[CrossRef](#)]
47. Pfaffl, M.W. A New Mathematical Model for Relative Quantification in Real-Time Rt-Pcr. *Nucleic Acids Res.* **2001**, *29*, e45. [[CrossRef](#)]
48. Leung, A.W.; Broton, C.; Bogacheva, M.S.; Xiao, A.Z.; Garcia-Castro, M.I.; Lou, Y.R. RNA-based CRISPR-Mediated Loss-of-Function Mutagenesis in Human Pluripotent Stem Cells. *J. Mol. Biol.* **2020**, *432*, 3956–3964. [[CrossRef](#)]
49. Pihlajamaki, J.; Boes, T.; Kim, E.Y.; Dearie, F.; Kim, B.W.; Schroeder, J.; Mun, E.; Nasser, I.; Park, P.J.; Bianco, A.C.; et al. Thyroid hormone-related regulation of gene expression in human fatty liver. *J. Clin. Endocrinol. Metab.* **2009**, *94*, 3521–3529. [[CrossRef](#)]
50. Fujimoto, N.; Kitamura, S.; Uramaru, N.; Miyagawa, S.; Iguchi, T. Identification of hepatic thyroid hormone-responsive genes in neonatal rats: Potential targets for thyroid hormone-disrupting chemicals. *Toxicol. Lett.* **2018**, *286*, 48–53. [[CrossRef](#)]
51. Yao, X.; Hou, S.; Zhang, D.; Xia, H.; Wang, Y.C.; Jiang, J.; Yin, H.; Ying, H. Regulation of fatty acid composition and lipid storage by thyroid hormone in mouse liver. *Cell Biosci.* **2014**, *4*, 38. [[CrossRef](#)]